Breakfast Innovation Theater (Non-Accredited): Impact, Assessment, and Treatment of Tardive Dyskinesia: A Focus on Patient-Reported Outcomes With a VMAT2 Inhibitor

Breakfast will be served. Seating is limited to 150 and will be available on a first-come, first-served basis. Please plan to arrive early to ensure a seat. No CE credits are offered at these programs. Presenter(s): Erin Crown, MHS, PA-C, CAQ-Psychiatry This presentation is sponsored by Neurocrine Biosciences, Inc.